Therapy resistance mechanisms in Ewing's sarcoma family tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 4, 2014, Pages 657-663

  Ahmed, Atif A ^a,c   Zia, Hamid ^a   Wagner, Lars ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

Chemotherapy resistance; Ewing's sarcoma; IGF1R; Signaling pathways

Indexed keywords

DRUG METABOLIZING ENZYME;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GENETICS; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; EWING SARCOMA; HUMAN; INHERITANCE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR RESISTANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; SARCOMA, EWING; SIGNAL TRANSDUCTION;

EID: 84898057441     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2392-1     Document Type: Review

References (64)

1. Balamuth NJ, Womer RB (2010) Ewing's sarcoma. Lancet Oncol 11(2):184-192
2. Ross KA, Smyth NA, Murawski CD, Kennedy JG (2013) The biology of Ewing sarcoma. ISRN Oncol 2013:759725
3. Kelleher FC, Thomas DM (2012) Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin Sarcoma Res 2(1):6
4. Ordóñez JL, Osuna D, Herrero D, de Alava E, Madoz-Gúrpide J (2009) Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res 69(18):7140-7150
5. Grier HE (1997) The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 44:991
6. Kissane JM, Askin FB, Foulkes M, Stratton LB, Shirley SF (1983) Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Hum Pathol 14:773
7. Arpaci E, Yetisyigit T, Seker M, Uncu D, Uyeturk U, Oksuzoglu B, Demirci U, Coskun U, Kucukoner M, IsIkdogan A, Inanc M, Alkis N, Ozkan M (2013) Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology. Med Oncol 30(1):469
8. Geryk-Hall M, Hughes DP (2009) Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr Oncol Rep 11(6):446-453
9. Johnson R, Humphreys SR (1969) Past failures and future possibilities in Ewing's sarcoma: experimental and preliminary clinical results. Cancer 23:161-166
10. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 30:4148-4154
11. Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, Santana VM, Pappo AS (2002) Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 94:561-569
12. Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B, Philip T (2001) Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 37:1338-1344
13. Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH (2013) Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol 14(Unit14):25
14. Honoki K (2010) Do stem-like cells play a role in drug resistance of sarcomas? Expert Rev Anticancer Ther 10(2):261-270
15. Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, Kong D, Sarkar FH (2012) Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets 16(10):1041-1054
16. Trucco M, Loeb D (2012) Sarcoma stem cells: do we know what we are looking for? Sarcoma 2012:291705
17. Monument MJ, Bernthal NM, Randall RL (2013) Salient features of mesenchymal stem cells-implications for Ewing sarcoma modeling. Front Oncol 3:24
18. Lin PP, Wang Y, Lozano G (2011) Mesenchymal stem cells and the origin of Ewing's sarcoma. Sarcoma 2011:276463
19. Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER (2010) CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 10:116
20. Saini V, Shoemaker RH (2010) Potential for therapeutic targeting of tumor stem cells. Cancer Sci 101(1):16-21
21. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M (2005) Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23(3):548-558
22. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, Serra M, Calabuig-Fariñas S, Picci P, Llombart-Bosch A (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 128:1139-1150
23. Dylla L, Moore C, Jedlicka P (2013) MicroRNAs in Ewing sarcoma. Front Oncol 3:65
24. Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T, Fujiwara-Okada Y, Hatano M, Nabashima A, Kamura S, Iwamoto Y (2013) miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 13(1):21
25. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K (2012) miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226(5):796-805
26. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL (2012) EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res 10(8):1098-1108
27. Navarro S, Giraudo P, Karseladze AI, Smirnov A, Petrovichev N, Savelov N, Alvarado-Cabrero I, Llombart-Bosch A (2007) Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications. Anticancer Res 27(4B):2457-2463
28. Greve B, Sheikh-Mounessi F, Kemper B, Ernst I, Götte M, Eich HT (2012) Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma. Strahlenther Onkol 188(11):1038-1047
29. Holt SV, Brookes KE, Dive C, Makin GW (2011) Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol Rep 25(4):1177-1181
30. Mitsiades N, Poulaki V, Leone A, Tsokos M (1999) Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J Natl Cancer Inst 91(19):1678-1684
31. Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M (1994) Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 102(1):61-67
32. Oda Y, Dockhorn-Dworniczak B, Jürgens H, Roessner A (1997) Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol 123(4):237-239
33. Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M, Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y (2006) Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer 118(1):90-97
34. Januchowski R, Wojtowicz K, Zabel M (2013) The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother 67(7):669-680
35. Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM (2010) High ALDH activity identifies chemotherapy- resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 5(11):e13943
36. Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, Hanada M, Iwamoto Y (2007) The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 31(4):803-811
37. Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22(47):7369-7375
38. Pasello M, Manara MC, Michelacci F, Fanelli M, Hattinger CM, Nicoletti G, Landuzzi L, Lollini PL, Caccuri A, Picci P, Scotlandi K, Serra M (2011) Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst) 34(3):131-145
39. Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 21(13):2481-2485
40. Scotlandi K (2006) Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 587:13-22
41. Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER (2013) COG Ewing Sarcoma Biology Committee. Biomarkers in Ewing sarcoma: the Promise and Challenge of Personalized Medicine. A report from the Children's Oncology Group. Front Oncol 3:141
42. van Maldegem AM, Hogendoorn PC, Hassan AB (2012) The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin Sarcoma Res 2(1):7
43. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT (2009) The insulin-like growth factor system and sarcomas. J Pathol 217(4):469-482
44. Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR (2011) Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011:402508
45. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D'Incalci M, Picci P, Scotlandi K (2005) The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 27(6):1605-1616
46. Kolb EA, Gorlick R (2009) Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 11(4):307-313
47. Olmos D, Tan DS, Jones RL, Judson IR (2010) Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 16(3):183-194
48. O'Neill A, Shah N, Zitomersky N, Ladanyi M, Shukla N, Uren A, Loeb D, Toretsky J (2013) Insulin-like growth factor 1 receptor as a therapeutic target in Ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma 2013:450478
49. Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, Marino MT, Conte A, Sigismund S, Carè A, Belfiore A, Picci P, Scotlandi K (2012) Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol 26(9):1603-1616
50. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30(24):2730-2740
51. Ahmed AA, Sherman AK, Pawel BR (2012) Expression of therapeutic targets in Ewing sarcoma family tumors. Hum Pathol 43(7):1077-1083
52. Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY (2012) MAPK/ERK signaling in osteosarcomas, Ewing sarcomas and chondrosarcomas: therapeutic implications and future directions. Sarcoma 2012:404810
53. Liu C, Zhang Z, Tang H, Jiang Z, You L, Lia Y (2013) Crosstalk between IGF-1R and other tumor promoting pathways. Curr Pharm Des 19:1-10
54. Wagner MJ, Maki RG (2013) Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Front Oncol 3:9
55. Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH (2013) ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med 5(7):1019-1034
56. Li L, Tibiche C, Fu C, Kaneko T, Moran MF, Schiller MR, Li SS, Wang E (2012) The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer. Genome Res 22(7):1222-1230
57. Diaz-Cano SalvadorJ (2012) Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci 13(2):1951-2011
58. Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108(3):479-485
59. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ (2009) The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69(19):7662-7671
60. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18(9):2625-2631
61. Huang S, Kauffman S (2013) How to escape the cancer attractor: rationale and limitations of multi-target drugs. Semin Cancer Biol 23(4):270-278
62. Huang S, Ernberg I, Kauffman S (2009) Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol 20(7):869-876
63. Csermely P, Korcsmáros T (2013) Cancer-related networks: a help to understand, predict and change malignant transformation. Semin Cancer Biol 23(4):209-212
64. Subbiah V, Kurzrock R (2012) Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med 13(73):405-415